Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Noncompartmental Analysis: Mean Residence Time01:05

Noncompartmental Analysis: Mean Residence Time

601
According to statistical moment theory, mean residence time (MRT) is an important measure in pharmacokinetics. MRT can be defined as the expected mean of a probability density function distribution. It provides valuable insights into drug disposition in the body.
After the administration of a drug through intravenous bolus injection, the drug molecules are distributed throughout the body and remain there for varying periods. The MRT represents the average time these drug molecules stay in the...
601
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

486
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
486
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

540
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
540
Treatment Strategies for Psychological Disorders01:24

Treatment Strategies for Psychological Disorders

774
Treatment approaches for psychological disorders fall into three main categories: psychological, biological, and sociocultural. Each approach targets different aspects of mental health, requiring varying levels of education and training.
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...
774
Bioavailability Enhancement: Drug Solubility Enhancement01:16

Bioavailability Enhancement: Drug Solubility Enhancement

261
Body:Bioavailability is a critical factor in determining a drug's effectiveness. It refers to the proportion of a drug that enters the circulation when introduced into the body and is, as a result, able to have an active effect. Enhancing bioavailability is essential for drugs with poor solubility, as it can significantly impact their therapeutic efficacy. Various methods are employed to increase the solubility of drugs, thereby enhancing their bioavailability.Micronization and nanonization are...
261
Bioavailability Enhancement: Drug Permeability Enhancement01:27

Bioavailability Enhancement: Drug Permeability Enhancement

205
Body:After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt...
205

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biologically engineered vectors enable topical mRNA delivery for skin regeneration.

Communications biology·2026
Same author

Cutaneous delivery of bioactive components from a rice bran oil nanoemulsion and their biodistribution in porcine and human skin.

International journal of pharmaceutics: X·2026
Same author

Comparing the efficacy of nanocarriers for cutaneous and follicular delivery of poorly water-soluble molecules: A case study with ciclosporin A.

International journal of pharmaceutics: X·2026
Same author

Bioanalytical UHPLC-MS/MS Method for Quantification of Terbinafine in Ungual Delivery Studies.

Biomedical chromatography : BMC·2026
Same author

3D printed system using <i>ex vivo</i> porcine eye globes to investigate intracorneal absorption of dexpanthenol from contact lens care solution and eye drops.

International journal of pharmaceutics: X·2026
Same author

Ionto phoretic delivery of caspofungin acetate to the cornea and sclera and its intracorneal biodistribution.

International journal of pharmaceutics: X·2025

Related Experiment Video

Updated: Feb 1, 2026

Platelet-Rich Plasma Lysate for Treatment of Eye Surface Diseases
05:57

Platelet-Rich Plasma Lysate for Treatment of Eye Surface Diseases

Published on: August 2, 2022

5.0K

Strategies for modifying drug residence time and ocular bioavailability to decrease treatment frequency for back of

Whitney Shatz1,2, Jeffrey Aaronson3, Stefan Yohe3

  • 1a Department of Protein Chemistry , Genentech , South San Francisco , CA , USA.

Expert Opinion on Drug Delivery
|November 30, 2018
PubMed
Summary

New biologic delivery technologies aim to improve treatment for posterior eye diseases, reducing the burden of frequent intravitreal injections. These innovations seek to offer longer-acting, patient-friendly options for conditions like age-related macular degeneration.

Keywords:
Posterior eye diseasesintravitreal injectionlong-acting deliveryocular devicespharmacokinetic modifiersslow release formulations

More Related Videos

Spatio-Temporal In Vivo Imaging of Ocular Drug Delivery Systems using Fiberoptic Confocal Laser Microendoscopy
07:12

Spatio-Temporal In Vivo Imaging of Ocular Drug Delivery Systems using Fiberoptic Confocal Laser Microendoscopy

Published on: September 27, 2021

2.8K
Clinical Application of Intense Pulsed Light Therapy and Radio Frequency for Treatment of Ocular Surface Diseases
07:36

Clinical Application of Intense Pulsed Light Therapy and Radio Frequency for Treatment of Ocular Surface Diseases

Published on: July 3, 2025

739

Related Experiment Videos

Last Updated: Feb 1, 2026

Platelet-Rich Plasma Lysate for Treatment of Eye Surface Diseases
05:57

Platelet-Rich Plasma Lysate for Treatment of Eye Surface Diseases

Published on: August 2, 2022

5.0K
Spatio-Temporal In Vivo Imaging of Ocular Drug Delivery Systems using Fiberoptic Confocal Laser Microendoscopy
07:12

Spatio-Temporal In Vivo Imaging of Ocular Drug Delivery Systems using Fiberoptic Confocal Laser Microendoscopy

Published on: September 27, 2021

2.8K
Clinical Application of Intense Pulsed Light Therapy and Radio Frequency for Treatment of Ocular Surface Diseases
07:36

Clinical Application of Intense Pulsed Light Therapy and Radio Frequency for Treatment of Ocular Surface Diseases

Published on: July 3, 2025

739

Area of Science:

  • Ophthalmology
  • Biotechnology
  • Pharmaceutical Sciences

Background:

  • Posterior eye diseases pose a significant global health challenge.
  • Current treatments, such as anti-VEGF injections, require frequent administration, impacting patient compliance and clinical resources.
  • There is a critical need for advanced, patient-centric therapeutic strategies for posterior segment ocular conditions.

Purpose of the Study:

  • To provide an overview of emerging technologies for delivering biologics to the posterior segment of the eye.
  • To highlight innovations aimed at extending the therapeutic half-life of ocular drugs.
  • To discuss the challenges hindering the clinical translation of novel drug delivery systems.

Main Methods:

  • Review of current literature on posterior eye disease treatments.
  • Analysis of emerging drug delivery technologies for ocular biologics.
  • Discussion of preclinical and clinical translation hurdles.

Main Results:

  • Several novel technologies are under investigation for sustained drug delivery to the back of the eye.
  • These technologies aim to overcome the limitations of conventional intravitreal injections.
  • Key challenges include patient education, preclinical-to-clinical translatability, and regulatory complexities.

Conclusions:

  • Emerging technologies offer promising alternatives to frequent intravitreal injections for posterior eye diseases.
  • Addressing translational and regulatory challenges is crucial for successful clinical implementation.
  • Further development is needed to realize patient-friendly, long-acting ocular therapeutics.